Pharmacokinetics and pharmacodynamics of biapenem in critically ill patients under continuous venovenous hemodiafiltration

Japanese Journal of Antibiotics

Volumn 61, Issue 5, 2008, Pages 303-313

  Suyama, Hidemichi ^a   Ikawa, Kazuro ^a   Morikawa, Norifumi ^a   Ikeda, Kayo ^a   Fujiue, Yoshihiro ^a   Morikawa, Shingo ^a   Kaneko, Kotaro ^a   Kuwabara, Masao ^b   Yamanoue, Takao ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIAPENEM; OMEGACIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTINUOUS HEMODIAFILTRATION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; JAPAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OPEN STUDY; PHARMACODYNAMICS; PLASMA; PROBABILITY; PROSPECTIVE STUDY; SEPSIS;

ADULT; AGED; CRITICAL ILLNESS; DROSOPHILA PROTEINS; DRUG RESISTANCE, BACTERIAL; FEMALE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, ACUTE; MALE; MIDDLE AGED; MONTE CARLO METHOD; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PSEUDOMONAS AERUGINOSA; SEPSIS; THERAPEUTIC EQUIVALENCY; THIENAMYCINS; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 57849162510     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. PERRY, C. M. & T. IBBOTSON: Biapenem. Drugs 62: 2221-2234, 2002
2. HEERING, P.; S. MORGERA, F. J. SCHMITZ, et al.: Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med. 23: 288-296, 1997
3. DELLINGER, R. P.; J. M. CARLET, H. MASUR, et al.: Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit. Care Med. 32: 858-873, 2004
4. DRUSANO, G. L.: Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36 (Suppl. 1): S42-S50, 2003
5. TAKATA, T.; K. AIZAWA, A. SHIMIZU, et al.: Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J. Infect. Chemother. 10: 76-85, 2004
6. DRUSANO, G. L.; S. L. PRESTON, C. HARDALO, et al.: Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45: 13-22, 2001
7. MOUTON, J. W.; M. N. DUDLEY, O. CARS, et al.: Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55: 601-607, 2005
8. IKEDA, K.; K. IKAWA, A. IKEDA, et al.: A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 844: 148-152, 2006
9. YAMAOKA, K.; Y. TANIGAWARA, T. NAKAGAWA, et al.: A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 4: 879-885, 1981
10. GILES, L. J.; A. C. JENNINGS, A. H. THOMSON, et al.: Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit. Care Med. 28: 632-637, 2000
11. YAMASHITA, N.; K., KAWASHIMA, K. NOMURA, et al.: Pharmacokinetics of biapenem in laboratory animals. Chemotherapy (Tokyo) 42 (S4): 243-250, 1994
12. FISH, D. N.; I. TEITELBAUM & E. ABRAHAM: Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother. 49: 2421-2428, 2005
13. KOEPPE, P.; D. HOFFLER & B. FITZEN: Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneim.-Forsch. 47: 1250-1256, 1997
14. THALHAMMER, F. & W. H. HORL: Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy. Clin. Pharmacokinet. 39: 271-279, 2000
15. MARIAT, C.; C. VENET, F. JEHL, et al.: Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit. Care 10: R26, 2006
16. LEROY, A.; F. LEGUY, F. BORSA, et al.: Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob. Agents Chemother. 25: 638-642, 1984
17. KOZAWA, O.; T. UEMATSU, H. MATSUNO, et al.: Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob. Agents Chemother. 42: 1433-1436, 1998
18. KUTI, J. L.; C. H. NIGHTINGALE & D. P. NICOLAU: Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 48: 2464-2470, 2004
19. MIKAMO, H. & K. TOTSUKA: The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation. Jpn. J. Antibiotics 58: 159-167, 2005 (in Japanese)
20. POWER, B. M.; A. M. FORBES, P. V. VAN HEERDEN, et al.: Pharmacokinetics of drugs used in critically ill adults. Clin. Pharmacokinet. 34: 25-56, 1998